Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2013

View Archived Issues

Characterization of a small-molecule dual receptor inhibitor that targets oncogenic pathways

Ipsen aims to expand neurology R&D capabilities with acquisition of Syntaxin

First-in-human results presented for LY-2951742

Pluristem's PLX cells tested for treatment of radiation poisoning

Novel tyrosine-protein kinase inhibitors disclosed by Allergan

A novel adeno-associated virus gene therapy for mucopolysaccharidosis IIIA

AbbVie presents new TRPV1 antagonists for pain and other disorders

Merck & Co. synthesizes novel Hdm2 inhibitors

Biosortia and AstraZeneca enter drug discovery research agreement

Oryzon obtains European orphan drug designation for ORY-1001 in AML

OncoGenex completes patient enrollment in Borealis-1 trial in metastatic bladder cancer

Life Technologies and Merck Serono enter collaboration

FDA accepts Iroko's NDA for low-dose submicron indomethacin

Chinese group divulges novel FLT3 inhibitors

Toyama Chemical presents phase II results for T-817MA

Advanomics receives research grant to advance lead anticancer candidate

New protein kinase and apoptosis inducers reported by Bayer

Updated xTAG CYP2D6 Kit receives FDA and European clearance

Medivir describes new agents for HCV infection

Sequella obtains exclusive worldwide license to TB treatment candidate from Pfizer

Abide Therapeutics and UC San Diego receive grant to validate MAGL target

New mouse model of CD30-positive T-cell lymphoma described

Qualigen obtains 510(k) clearance from FDA for FastPack Vitamin D Immunoassay

Paladin Labs becomes sole shareholder of Allon Therapeutics

Basilea provides update on phase III program for isavuconazole

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...